Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by Corvus Pharmaceuticals, Inc. on June 13, 2024. The record date for the meeting was April 18, 2024, with 49,038,582 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
A total of 35,968,782 shares were voted in person or by proxy. The results for the three proposals were as follows:
- Proposal 1 (Election of Director): Scott W. Morrison was elected as a Class II Director. He received 19,667,286 votes for, 5,398,946 votes withheld, and there were 10,902,550 broker non-votes.
- Proposal 2 (Ratification of Accounting Firm): Stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The vote was 35,776,658 for, 65,997 against, and 126,127 abstentions.
- Proposal 3 (Executive Compensation): Stockholders approved the non-binding advisory vote on the compensation of Named Executive Officers. The vote was 24,424,413 for, 413,670 against, 234,233 abstentions, and 10,896,466 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Scott W. Morrison's term as a Class II Director extends until the 2027 Annual Meeting.
- PricewaterhouseCoopers LLC is confirmed as the auditor for the fiscal year ending December 31, 2024.
- Approximately 22% of outstanding shares (10.9 million) were broker non-votes on the director election, and approximately 22% (10.9 million) were broker non-votes on the executive compensation vote.
- The filing contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for financial metrics.